Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ben Tre Pharmaceutical JSCSTC:DBT 14 Intrinsic Value: Projected FCF is ₫0.00 as of Sep. 12, 2026. GuruFocus rates STC:DBT with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 635 Drug Manufacturers companies, Ben Tre Pharmaceutical JSC ranks worse than 157480.16% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Ben Tre Pharmaceutical JSC's Intrinsic Value: Projected FCF or its related term are showing as below:
STC:DBT's Price-to-Projected-FCF is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.51 * Ranked among companies with meaningful Price-to-Projected-FCF only.
Ben Tre Pharmaceutical JSC (STC:DBT) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Ben Tre Pharmaceutical JSC's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
13000.00
/
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ben Tre Pharmaceutical JSC Intrinsic Value: Projected FCF Related Terms
Ben Tre Pharmaceutical JSC Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Ben Tre Pharmaceutical JSC's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ben Tre Pharmaceutical JSC Intrinsic Value: Projected FCF Chart
Ben Tre Pharmaceutical JSC Annual Data
Trend
Intrinsic Value: Projected FCF
Ben Tre Pharmaceutical JSC Semi-Annual Data
Intrinsic Value: Projected FCF
STC:DBT vs ZTS, UTHR, VTRS: Intrinsic Value: Projected FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ben Tre Pharmaceutical JSC's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ben Tre Pharmaceutical JSC Price-to-Projected-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ben Tre Pharmaceutical JSC's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Ben Tre Pharmaceutical JSC's Price-to-Projected-FCF falls into.
Ben Tre Pharmaceutical JSC Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
What does a Intrinsic Value: Projected FCF of ₫0.00 mean?
Ben Tre Pharmaceutical JSC (STC:DBT) has a Intrinsic Value: Projected FCF of ₫0.00 as of Sep. 12, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Ben Tre Pharmaceutical JSC and its competitors. According to the industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 635 companies in the Drug Manufacturers industry.
Is Ben Tre Pharmaceutical JSC's Intrinsic Value: Projected FCF too high?
Ben Tre Pharmaceutical JSC's current Intrinsic Value: Projected FCF is ₫0.00. Based on the distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 635 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ben Tre Pharmaceutical JSC has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Ben Tre Pharmaceutical JSC's Intrinsic Value: Projected FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 635 companies for Intrinsic Value: Projected FCF. This places Ben Tre Pharmaceutical JSC in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Drug Manufacturers company?
The median Intrinsic Value: Projected FCF among Drug Manufacturers companies is 1.51, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Ben Tre Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median Intrinsic Value: Projected FCF is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ben Tre Pharmaceutical JSC's current Intrinsic Value: Projected FCF is ₫0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ben Tre Pharmaceutical JSC stock overvalued right now?
Ben Tre Pharmaceutical JSC (STC:DBT) has a current Intrinsic Value: Projected FCF of ₫0.00. The current Intrinsic Value: Projected FCF is ₫0.00. Ben Tre Pharmaceutical JSC's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Ben Tre Pharmaceutical JSC (STC:DBT), the current Intrinsic Value: Projected FCF is ₫0.00 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ben Tre Pharmaceutical JSC is based in Vietnam. The company is engaged in trading in pharmaceuticals, functional foods, vaccines, cosmetics, medical equipment, & medical machinery. It is also engaged in the Import and export of testing chemicals & biological products, Manufacturing medicines for human treatment, producing pharmaceuticals, chemicals, and medicinal herbs, and Leasing warehouses and premises.
14GF Score
Get the complete analysis for STC:DBT
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DBT has been successfully added to your 
